Back

Cancer persister cells activate NMDARs to survive ferroptosis

PUNZI, S.; VILLANTI, I.; GATTI, G.; CITTARO, D.; CRUPI, G.; PRUNELLA, M.; ALTINI, N.; CASAROLI, G.; GUERRERA, E.; GALLO, G. F. M.; FELICI, C.; BOTRUGNO, O. A.; TANZI, E.; BEVILACQUA, V.; NAI, A.; SILVESTRI, L.; TONON, G.

2026-07-14 cancer biology
10.64898/2026.07.13.738168 bioRxiv
Show abstract

Upon treatment, cancer cells engage non-genetic adaptations, including tolerance and subsequent persistence, to survive therapy. Eliciting programmed cancer cell death in these persister cells (PCs) remains a primary goal in oncology. We found that ferroptosis is the programmed cell death mechanism most deregulated in persisters by some of the most widely used therapeutic regimens, including platinum-based therapies, which combined with ferroptosis inducers ablate persister colorectal cancer cells. Conversely, persisters emerging from topoisomerase inhibitor regimens withstand ferroptosis and ferroptotic inducers, increasing instead intracellular iron concentration. We found that topoisomerase inhibitors trigger the Xc- antiporter axis (via SLC7A11 and CD44) increasing both intracellular cystine, to activate GPX4, and extracellular glutamate. Glutamate then engages the NMDA receptors (NMDARs), which are essential in neurotransmission but recently reported to be deregulated also in cancer cells. In PCs, NMDARs stimulate intracellular Ca2+ uptake and trigger the AKT/NFE2L2 axis, thereby engaging a cytoprotective program to cope with oxidative stress. Furthermore, we found that NFE2L2 increases the distance between the endoplasmic reticulum and mitochondria while reducing mitochondrial ROS in PCs. The synergistic inhibition of both the standard (Xc- antiporter) and this novel NMDAR/NFE2L2 axis resensitizes PCs to ferroptosis. These data provide new opportunities to improve the efficacy of widely used therapeutic regimens. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=114 SRC="FIGDIR/small/738168v1_ufig1.gif" ALT="Figure 1"> View larger version (33K): org.highwire.dtl.DTLVardef@1f32868org.highwire.dtl.DTLVardef@e1c7eborg.highwire.dtl.DTLVardef@10c4d25org.highwire.dtl.DTLVardef@9ce6d6_HPS_FORMAT_FIGEXP M_FIG C_FIG O_LIPersister cells induced by FOLFOX are sensitive to ferroptosis while resistant upon FOLFIRI treatment C_LIO_LIIncreased extracellular glutamate activates a NMDAR/NFE2L2 axis C_LIO_LINFE2L2 copes with oxidative stress by inhibiting juxtaposition between ER and mitochondria C_LIO_LIInhibition of Xc- antiporter alongside NMDAR/NFE2L2 is required to trigger ferroptosis in FOLFIRI persister cells C_LI

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
Cell Reports
1498 papers in training set
Top 2%
9.6%
2
Cancer Discovery
66 papers in training set
Top 0.3%
6.6%
3
Nature Communications
5641 papers in training set
Top 24%
6.6%
4
Cell
431 papers in training set
Top 1%
5.4%
5
Cell Stem Cell
62 papers in training set
Top 0.3%
5.1%
6
EMBO Molecular Medicine
95 papers in training set
Top 0.2%
4.0%
7
Cell Reports Medicine
153 papers in training set
Top 0.7%
4.0%
8
Clinical Cancer Research
64 papers in training set
Top 0.6%
3.4%
9
Journal of Clinical Investigation
179 papers in training set
Top 2%
3.2%
10
Cancer Research
130 papers in training set
Top 1%
3.2%
50% of probability mass above
11
Cancer Cell
42 papers in training set
Top 0.4%
3.2%
12
Science Advances
1243 papers in training set
Top 12%
3.1%
13
eLife
5828 papers in training set
Top 39%
2.6%
14
Nature Cancer
39 papers in training set
Top 0.7%
2.3%
15
Molecular Cell
350 papers in training set
Top 3%
2.3%
16
The EMBO Journal
309 papers in training set
Top 2%
2.3%
17
EMBO Reports
263 papers in training set
Top 3%
2.1%
18
Cells
249 papers in training set
Top 4%
1.5%
19
Genome Medicine
183 papers in training set
Top 3%
1.3%
20
Molecular Cancer Therapeutics
40 papers in training set
Top 0.6%
1.3%
21
Journal of Experimental Medicine
119 papers in training set
Top 2%
1.1%
22
iScience
1154 papers in training set
Top 29%
1.0%
23
Science Signaling
65 papers in training set
Top 1%
1.0%
24
JCI Insight
277 papers in training set
Top 7%
1.0%
25
Oncogene
85 papers in training set
Top 2%
0.8%
26
Cancer Research Communications
51 papers in training set
Top 2%
0.8%
27
Signal Transduction and Targeted Therapy
30 papers in training set
Top 0.9%
0.6%
28
Journal for ImmunoTherapy of Cancer
75 papers in training set
Top 2%
0.6%
29
Communications Biology
993 papers in training set
Top 36%
0.6%
30
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 46%
0.6%